We present the results of 53 stage I-III nephroblastoma pediatric patients treated in Belarusia from 2005 to 2010. All the patients received adjuvant chemotherapy (according to SIOP WT 2001 protocol), surgery (complete or partial nephrectomy) and neoadjuvant chemotherapy. The prolonged adjuvant chemotherapy was proposed in patients with good response as a cytoreductive measure enabling organ-sparing surgery. Five-year event-free survival was 91+/-6% in complete and 89+/-9% in partial nephrectomy recipients (p=0,64). Our experience suggest the feasibility of prolonged adjuvant chemoradiotherapy in patients with good clinical response and no contraindications for complete nephrectomy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Introduction: Sarcomas are rare cancers originating from mesenchymal tissues, manifesting in diverse anatomical locations, but notably in connective tissue, muscles and the skeleton. Thoracic sarcomas present a unique diagnostic and surgical challenge attributable to their rarity and pathoanatomy. Standard practice currently comprises wide surgical excision, often accompanied by adjuvant chemotherapy and/or radiotherapy.
View Article and Find Full Text PDFThe translational potential of epigenetic modulatory bioactive phytochemicals as adjuvant therapy against cancer.
Int Rev Cell Mol Biol
January 2025
Department of Biochemistry, CSIR-Central Food Technological Research Institute, Mysore, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India. Electronic address:
In preclinical studies, bioactive phytochemicals have shown enormous potential therapeutic efficacy against various human malignancies. These natural compounds have been shown to possess an inherent potential to alter the molecular signaling pathways and epigenetic modulatory activity involved in multiple physiological functions. Recently, epigenetic therapy has emerged as an important therapeutic modality due to the reversible nature of epigenetic alterations.
View Article and Find Full Text PDFGiant mesenteric cysts: Clinical insights and diagnostic challenges.
Int J Surg Case Rep
January 2025
Damascus University, University Pediatrics' Hospital, Damascus, Syria.
Introduction And Significance: Giant mesenteric cysts are rare and their clinical presentation varies depending on their location and size and therefore varies widely in clinical manifestations. Many theories have attempted to explain the occurrence of these tumors but no precise cause has been found. However, surgical excision is the gold standard in the treatment of these tumors and there is no need for adjuvant radiotherapy or chemotherapy.
View Article and Find Full Text PDFPrognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study.
Sci Rep
January 2025
Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
Management of melanoma has changed significantly with the discovery of targeted therapies and immune checkpoint inhibitors (ICI). Our aim in the study is to determine which treatment alternatives, specifically dabrafenib plus trametinib and ICIs, are effective in adjuvant therapy and which treatment is effective as first-line metastatic therapy. This retrospective, multicenter study included 120 patients diagnosed with stage IIIB-IIID melanoma receiving both adjuvant and first-line metastatic treatment between 2007 and 2023.
View Article and Find Full Text PDF[Research progress in neoadjuvant therapy for epithelial ovarian cancer].
Zhonghua Fu Chan Ke Za Zhi
January 2025
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!